Hikma Pharmaceuticals Plc (HKMPF)
19.10
-0.40
(-2.05%)
USD |
OTCM |
May 19, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 4.145B |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -26.02% |
| Valuation | |
| PE Ratio | 10.52 |
| PE Ratio (Forward) | |
| PS Ratio | 1.262 |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | 0.48 |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -- |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 88.90% |
Profile
| Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. It operates through the following segments: Branded, Injectables, and Rx. The Branded segment sells branded generics and in-licensed patented products in the Middle East and North Africa. The Injectables segment includes generic injectable products distributed globally and primarily used in hospitals. The Rx segment includes oral, respiratory and other generic and specialty products supplied to the North American retail market, leveraging state-of-the-art manufacturing facility in Columbus, Ohio. The company was founded by Samih Taleb Darwazah in 1978 and is headquartered in London, the United Kingdom. |
| URL | http://www.hikma.com |
| Investor Relations URL | N/A |
| HQ State/Province | Greater London |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Aug. 06, 2026 (est.) |
| Last Earnings Release | Feb. 26, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 20, 2026 |
Profile
| Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. It operates through the following segments: Branded, Injectables, and Rx. The Branded segment sells branded generics and in-licensed patented products in the Middle East and North Africa. The Injectables segment includes generic injectable products distributed globally and primarily used in hospitals. The Rx segment includes oral, respiratory and other generic and specialty products supplied to the North American retail market, leveraging state-of-the-art manufacturing facility in Columbus, Ohio. The company was founded by Samih Taleb Darwazah in 1978 and is headquartered in London, the United Kingdom. |
| URL | http://www.hikma.com |
| Investor Relations URL | N/A |
| HQ State/Province | Greater London |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Aug. 06, 2026 (est.) |
| Last Earnings Release | Feb. 26, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 20, 2026 |